Burst Spinal Cord Stimulation in the Management of Chronic Pain : Current Perspectives
Copyright © 2022, Author(s)..
Over the last several decades, opioid diversion, misuse, and over-prescription have run rampant in the United States. Spinal cord stimulation (SCS) has been FDA approved for treatment for a primary indication of neuropathic limb pain that is resistant to more conservative medical therapy. The disorders qualified for treatment include neuropathic, post-surgical, post-amputation, osteodegenerative, and pain related to vascular disease. Some of the most frequently cited conditions for treatment of SCS include failed back surgery syndrome, complex regional pain syndrome (CRPS) Type I and Type II, and post-herpetic neuralgias. Developments in SCS systems have led to the differentiation between the delivered electromechanical waveform patterns, including tonic, burst, and high-frequency. Burst SCS mitigates traditional paresthesia due to expedited action potential and offers improved pain relief. Burst SCS has been shown in available studies to be non-inferior to the traditional SCS, which can cause pain paresthesia in patients who already have chronic pain. Burst SCS does not seem to cause or need the paresthesia seen in traditional SCS, making SCS not tolerable to patients. Moreover, some studies suggest that burst SCS may decrease opioid consumption in patients with chronic pain. This can make burst SCS an extremely useful tool in the battle against chronic pain and the raging opioid epidemic. As of now, more research needs to be performed to further delineate the effectiveness and long-term safety of this device.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Anesthesiology and pain medicine - 12(2022), 2 vom: 11. Apr., Seite e126416 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Edinoff, Amber N [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Burst Stimulation |
|---|
| Anmerkungen: |
Date Revised 28.09.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.5812/aapm-126416 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346743958 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346743958 | ||
| 003 | DE-627 | ||
| 005 | 20231226032201.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5812/aapm-126416 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1155.xml |
| 035 | |a (DE-627)NLM346743958 | ||
| 035 | |a (NLM)36158139 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Edinoff, Amber N |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Burst Spinal Cord Stimulation in the Management of Chronic Pain |b Current Perspectives |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.09.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2022, Author(s). | ||
| 520 | |a Over the last several decades, opioid diversion, misuse, and over-prescription have run rampant in the United States. Spinal cord stimulation (SCS) has been FDA approved for treatment for a primary indication of neuropathic limb pain that is resistant to more conservative medical therapy. The disorders qualified for treatment include neuropathic, post-surgical, post-amputation, osteodegenerative, and pain related to vascular disease. Some of the most frequently cited conditions for treatment of SCS include failed back surgery syndrome, complex regional pain syndrome (CRPS) Type I and Type II, and post-herpetic neuralgias. Developments in SCS systems have led to the differentiation between the delivered electromechanical waveform patterns, including tonic, burst, and high-frequency. Burst SCS mitigates traditional paresthesia due to expedited action potential and offers improved pain relief. Burst SCS has been shown in available studies to be non-inferior to the traditional SCS, which can cause pain paresthesia in patients who already have chronic pain. Burst SCS does not seem to cause or need the paresthesia seen in traditional SCS, making SCS not tolerable to patients. Moreover, some studies suggest that burst SCS may decrease opioid consumption in patients with chronic pain. This can make burst SCS an extremely useful tool in the battle against chronic pain and the raging opioid epidemic. As of now, more research needs to be performed to further delineate the effectiveness and long-term safety of this device | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Burst Stimulation | |
| 650 | 4 | |a Chronic Pain Management | |
| 650 | 4 | |a Complex Regional Pain Syndrome | |
| 650 | 4 | |a Failed Back Surgery Syndrome | |
| 650 | 4 | |a Neuropathic Pain | |
| 650 | 4 | |a Spinal Cord Stimulation | |
| 700 | 1 | |a Kaufman, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Alpaugh, E Saunders |e verfasserin |4 aut | |
| 700 | 1 | |a Lawson, Jesse |e verfasserin |4 aut | |
| 700 | 1 | |a Apgar, Tucker L |e verfasserin |4 aut | |
| 700 | 1 | |a Imani, Farnad |e verfasserin |4 aut | |
| 700 | 1 | |a Khademi, Seyed-Hossein |e verfasserin |4 aut | |
| 700 | 1 | |a Cornett, Elyse M |e verfasserin |4 aut | |
| 700 | 1 | |a Kaye, Alan D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anesthesiology and pain medicine |d 2011 |g 12(2022), 2 vom: 11. Apr., Seite e126416 |w (DE-627)NLM232579202 |x 2228-7531 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:2 |g day:11 |g month:04 |g pages:e126416 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5812/aapm-126416 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 2 |b 11 |c 04 |h e126416 | ||